Search

Your search keyword '"Calton, Elizabeth"' showing total 34 results
Start Over Author "Calton, Elizabeth"
34 results on '"Calton, Elizabeth"'

1. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

Author

Wienke, Judith, Visser, Lindy L., Kholosy, Waleed M., Keller, Kaylee M., Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R., Matser, Yvette A.H., Tas, Michelle L., Langenberg, Karin P.S., Lijnzaad, Philip, Borst, Anne L., Zappa, Elisa, Bergsma, Francisca J., Strijker, Josephine G.M., Verhoeven, Bronte M., Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M., Holstege, Frank C.P., Gray, Juliet C., Tytgat, Godelieve A.M., Scheijde-Vermeulen, Marijn A., Wijnen, Marc H.W.A., Dierselhuis, Miranda P., Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J.R., Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R., Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N., Margaritis, Thanasis, van Noesel, Max M., and Molenaar, Jan J.

Published
2024
Full Text
View/download PDF

2. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Author

Berlak, Mareike, Tucker, Elizabeth, Dorel, Mathurin, Winkler, Annika, McGearey, Aleixandria, Rodriguez-Fos, Elias, da Costa, Barbara Martins, Barker, Karen, Fyle, Elicia, Calton, Elizabeth, Eising, Selma, Ober, Kim, Hughes, Deborah, Koutroumanidou, Eleni, Carter, Paul, Stankunaite, Reda, Proszek, Paula, Jain, Neha, Rosswog, Carolina, Dorado-Garcia, Heathcliff, Molenaar, Jan Jasper, Hubank, Mike, Barone, Giuseppe, Anderson, John, Lang, Peter, Deubzer, Hedwig Elisabeth, Künkele, Annette, Fischer, Matthias, Eggert, Angelika, Kloft, Charlotte, Henssen, Anton George, Boettcher, Michael, Hertwig, Falk, Blüthgen, Nils, Chesler, Louis, and Schulte, Johannes Hubertus

Published
2022
Full Text
View/download PDF

4. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

Author

Afd Biomol.Mass Spect. and Proteomics, Sub Biomol.Mass Spectrometry & Proteom., Afd Pharmaceutics, Biomolecular Mass Spectrometry and Proteomics, Pharmaceutics, Wienke, Judith, Visser, Lindy L, Kholosy, Waleed M, Keller, Kaylee M, Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R, Matser, Yvette A H, Tas, Michelle L, Langenberg, Karin P S, Lijnzaad, Philip, Borst, Anne L, Zappa, Elisa, Bergsma, Francisca J, Strijker, Josephine G M, Verhoeven, Bronte M, Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M, Holstege, Frank C P, Gray, Juliet C, Tytgat, Godelieve A M, Scheijde-Vermeulen, Marijn A, Wijnen, Marc H W A, Dierselhuis, Miranda P, Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J R, Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R, Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N, Margaritis, Thanasis, van Noesel, Max M, Molenaar, Jan J, Afd Biomol.Mass Spect. and Proteomics, Sub Biomol.Mass Spectrometry & Proteom., Afd Pharmaceutics, Biomolecular Mass Spectrometry and Proteomics, Pharmaceutics, Wienke, Judith, Visser, Lindy L, Kholosy, Waleed M, Keller, Kaylee M, Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R, Matser, Yvette A H, Tas, Michelle L, Langenberg, Karin P S, Lijnzaad, Philip, Borst, Anne L, Zappa, Elisa, Bergsma, Francisca J, Strijker, Josephine G M, Verhoeven, Bronte M, Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M, Holstege, Frank C P, Gray, Juliet C, Tytgat, Godelieve A M, Scheijde-Vermeulen, Marijn A, Wijnen, Marc H W A, Dierselhuis, Miranda P, Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J R, Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R, Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N, Margaritis, Thanasis, van Noesel, Max M, and Molenaar, Jan J

Published
2024

5. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

Author

CTI Nierkens, Cancer, Infection & Immunity, CTI Research, Pathologie Pathologen staf, Onderzoek Beeld, Wienke, Judith, Visser, Lindy L, Kholosy, Waleed M, Keller, Kaylee M, Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R, Matser, Yvette A H, Tas, Michelle L, Langenberg, Karin P S, Lijnzaad, Philip, Borst, Anne L, Zappa, Elisa, Bergsma, Francisca J, Strijker, Josephine G M, Verhoeven, Bronte M, Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M, Holstege, Frank C P, Gray, Juliet C, Tytgat, Godelieve A M, Scheijde-Vermeulen, Marijn A, Wijnen, Marc H W A, Dierselhuis, Miranda P, Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J R, Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R, Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N, Margaritis, Thanasis, van Noesel, Max M, Molenaar, Jan J, CTI Nierkens, Cancer, Infection & Immunity, CTI Research, Pathologie Pathologen staf, Onderzoek Beeld, Wienke, Judith, Visser, Lindy L, Kholosy, Waleed M, Keller, Kaylee M, Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R, Matser, Yvette A H, Tas, Michelle L, Langenberg, Karin P S, Lijnzaad, Philip, Borst, Anne L, Zappa, Elisa, Bergsma, Francisca J, Strijker, Josephine G M, Verhoeven, Bronte M, Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M, Holstege, Frank C P, Gray, Juliet C, Tytgat, Godelieve A M, Scheijde-Vermeulen, Marijn A, Wijnen, Marc H W A, Dierselhuis, Miranda P, Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J R, Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R, Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N, Margaritis, Thanasis, van Noesel, Max M, and Molenaar, Jan J

Published
2024

7. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

Author

Chesler, Louis, Poon, Eva, Liang, Tong, Jamin, Yann, Walz, Susanne, Kwok, Colin, Hakkert, Anne, Barker, Karen, Urban, Zuzanna, Thwway, Khin, Zeid, Rhamy, Hallsworth, Albert, Box, Gary, Ebus, Marli E., Licciardello, Marco P., Sbirkov, Yordan, Lazaro, Glori, and Calton, Elizabeth

Subjects
Kinase inhibitors -- Usage, Transcription factors -- Health aspects, Neuroblastoma -- Drug therapy, Health care industry
Abstract

The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show that CYCO65 (fadraciclib), a clinical inhibitor of CDK9 and CDK2, selectively targeted MYOV-amplified neuroblastoma via multiple mechanisms. CDK9--a component of the transcription elongation complex P-TEFb--bound to the MYCAf-amplicon superenhancer, and its inhibition resulted in selective loss of nascent MYCN transcription. MYCN loss led to growth arrest, sensitizing cells for apoptosis following CDK2 inhibition. In MYCAf-amplified neuroblastoma, MYCN invaded active enhancers, driving a transcriptionally encoded adrenergic gene expression program that was selectively reversed by CYCO65. MYCN overexpression in mesenchymal neuroblastoma was sufficient to induce adrenergic identity and sensitize cells to CYCO65. CYCO65, used together with temozolomide, a reference therapy for relapsed neuroblastoma, caused long-term suppression of neuroblastoma growth in vivo, highlighting the clinical potential of CDK9/2 inhibition in the treatment of MYCAf-amplified neuroblastoma., Introduction The prominent role of Myc family protooncogene transcription factors (TFs) (MYC, MYCN, MYCL) in the genesis of adult and childhood cancers makes these TFs attractive targets for drug discovery [...]

Published
2020
Full Text
View/download PDF

8. Data from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

Author

Tucker, Elizabeth R., primary, Jiménez, Irene, primary, Chen, Lindi, primary, Bellini, Angela, primary, Gorrini, Chiara, primary, Calton, Elizabeth, primary, Gao, Qiong, primary, Che, Harvey, primary, Poon, Evon, primary, Jamin, Yann, primary, Martins Da Costa, Barbara, primary, Barker, Karen, primary, Shrestha, Sumana, primary, Hutchinson, J. Ciaran, primary, Dhariwal, Simran, primary, Goodman, Angharad, primary, Del Nery, Elaine, primary, Gestraud, Pierre, primary, Bhalshankar, Jaydutt, primary, Iddir, Yasmine, primary, Saberi-Ansari, Elnaz, primary, Saint-Charles, Alexandra, primary, Geoerger, Birgit, primary, Marques Da Costa, Maria Eugénia, primary, Pierre-Eugène, Cécile, primary, Janoueix-Lerosey, Isabelle, primary, Decaudin, Didier, primary, Nemati, Fariba, primary, Carcaboso, Angel M., primary, Surdez, Didier, primary, Delattre, Olivier, primary, George, Sally L., primary, Chesler, Louis, primary, Tweddle, Deborah A., primary, and Schleiermacher, Gudrun, primary

Published
2023
Full Text
View/download PDF

9. Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

Author

Tucker, Elizabeth R., primary, Jiménez, Irene, primary, Chen, Lindi, primary, Bellini, Angela, primary, Gorrini, Chiara, primary, Calton, Elizabeth, primary, Gao, Qiong, primary, Che, Harvey, primary, Poon, Evon, primary, Jamin, Yann, primary, Martins Da Costa, Barbara, primary, Barker, Karen, primary, Shrestha, Sumana, primary, Hutchinson, J. Ciaran, primary, Dhariwal, Simran, primary, Goodman, Angharad, primary, Del Nery, Elaine, primary, Gestraud, Pierre, primary, Bhalshankar, Jaydutt, primary, Iddir, Yasmine, primary, Saberi-Ansari, Elnaz, primary, Saint-Charles, Alexandra, primary, Geoerger, Birgit, primary, Marques Da Costa, Maria Eugénia, primary, Pierre-Eugène, Cécile, primary, Janoueix-Lerosey, Isabelle, primary, Decaudin, Didier, primary, Nemati, Fariba, primary, Carcaboso, Angel M., primary, Surdez, Didier, primary, Delattre, Olivier, primary, George, Sally L., primary, Chesler, Louis, primary, Tweddle, Deborah A., primary, and Schleiermacher, Gudrun, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

Author

Tucker, Elizabeth R., primary, Jiménez, Irene, primary, Chen, Lindi, primary, Bellini, Angela, primary, Gorrini, Chiara, primary, Calton, Elizabeth, primary, Gao, Qiong, primary, Che, Harvey, primary, Poon, Evon, primary, Jamin, Yann, primary, Martins Da Costa, Barbara, primary, Barker, Karen, primary, Shrestha, Sumana, primary, Hutchinson, J. Ciaran, primary, Dhariwal, Simran, primary, Goodman, Angharad, primary, Del Nery, Elaine, primary, Gestraud, Pierre, primary, Bhalshankar, Jaydutt, primary, Iddir, Yasmine, primary, Saberi-Ansari, Elnaz, primary, Saint-Charles, Alexandra, primary, Geoerger, Birgit, primary, Marques Da Costa, Maria Eugénia, primary, Pierre-Eugène, Cécile, primary, Janoueix-Lerosey, Isabelle, primary, Decaudin, Didier, primary, Nemati, Fariba, primary, Carcaboso, Angel M., primary, Surdez, Didier, primary, Delattre, Olivier, primary, George, Sally L., primary, Chesler, Louis, primary, Tweddle, Deborah A., primary, and Schleiermacher, Gudrun, primary

Published
2023
Full Text
View/download PDF

11. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

Author

Tucker, Elizabeth R; https://orcid.org/0000-0003-3716-6605, Jiménez, Irene; https://orcid.org/0000-0002-3544-4045, Chen, Lindi; https://orcid.org/0000-0001-7223-4226, Bellini, Angela; https://orcid.org/0000-0001-7374-1887, Gorrini, Chiara; https://orcid.org/0000-0002-5239-6671, Calton, Elizabeth; https://orcid.org/0000-0002-3662-8401, Gao, Qiong; https://orcid.org/0000-0002-0406-1594, Che, Harvey; https://orcid.org/0000-0003-1011-4653, Poon, Evon; https://orcid.org/0000-0002-0616-2487, Jamin, Yann; https://orcid.org/0000-0003-0350-3757, Da Costa, Barbara Martins; https://orcid.org/0000-0002-8993-6790, Barker, Karen; https://orcid.org/0000-0002-2357-3894, Shrestha, Sumana; https://orcid.org/0000-0002-5368-0818, Hutchinson, J Ciaran; https://orcid.org/0000-0002-1708-2634, Dhariwal, Simran; https://orcid.org/0000-0003-2386-9748, Goodman, Angharad; https://orcid.org/0000-0002-3010-5757, Del Nery, Elaine; https://orcid.org/0000-0002-9654-5202, Gestraud, Pierre; https://orcid.org/0000-0002-3893-9879, Bhalshankar, Jaydutt; https://orcid.org/0000-0001-7184-943X, Iddir, Yasmine; https://orcid.org/0000-0002-7022-0725, Saberi-Ansari, Elnaz; https://orcid.org/0000-0003-2472-1075, Saint-Charles, Alexandra; https://orcid.org/0000-0001-7779-7669, Geoerger, Birgit; https://orcid.org/0000-0003-4361-3643, Da Costa, Maria Eugénia Marques; https://orcid.org/0000-0002-1498-603X, Pierre-Eugène, Cécile; https://orcid.org/0000-0002-0351-7211, Janoueix-Lerosey, Isabelle; https://orcid.org/0000-0003-0434-3003, Decaudin, Didier; https://orcid.org/0000-0003-2254-0043, Nemati, Fariba; https://orcid.org/0000-0001-8879-7592, Carcaboso, Angel M; https://orcid.org/0000-0002-8485-426X, Surdez, Didier; https://orcid.org/0000-0002-7118-7859, et al, Tucker, Elizabeth R; https://orcid.org/0000-0003-3716-6605, Jiménez, Irene; https://orcid.org/0000-0002-3544-4045, Chen, Lindi; https://orcid.org/0000-0001-7223-4226, Bellini, Angela; https://orcid.org/0000-0001-7374-1887, Gorrini, Chiara; https://orcid.org/0000-0002-5239-6671, Calton, Elizabeth; https://orcid.org/0000-0002-3662-8401, Gao, Qiong; https://orcid.org/0000-0002-0406-1594, Che, Harvey; https://orcid.org/0000-0003-1011-4653, Poon, Evon; https://orcid.org/0000-0002-0616-2487, Jamin, Yann; https://orcid.org/0000-0003-0350-3757, Da Costa, Barbara Martins; https://orcid.org/0000-0002-8993-6790, Barker, Karen; https://orcid.org/0000-0002-2357-3894, Shrestha, Sumana; https://orcid.org/0000-0002-5368-0818, Hutchinson, J Ciaran; https://orcid.org/0000-0002-1708-2634, Dhariwal, Simran; https://orcid.org/0000-0003-2386-9748, Goodman, Angharad; https://orcid.org/0000-0002-3010-5757, Del Nery, Elaine; https://orcid.org/0000-0002-9654-5202, Gestraud, Pierre; https://orcid.org/0000-0002-3893-9879, Bhalshankar, Jaydutt; https://orcid.org/0000-0001-7184-943X, Iddir, Yasmine; https://orcid.org/0000-0002-7022-0725, Saberi-Ansari, Elnaz; https://orcid.org/0000-0003-2472-1075, Saint-Charles, Alexandra; https://orcid.org/0000-0001-7779-7669, Geoerger, Birgit; https://orcid.org/0000-0003-4361-3643, Da Costa, Maria Eugénia Marques; https://orcid.org/0000-0002-1498-603X, Pierre-Eugène, Cécile; https://orcid.org/0000-0002-0351-7211, Janoueix-Lerosey, Isabelle; https://orcid.org/0000-0003-0434-3003, Decaudin, Didier; https://orcid.org/0000-0003-2254-0043, Nemati, Fariba; https://orcid.org/0000-0001-8879-7592, Carcaboso, Angel M; https://orcid.org/0000-0002-8485-426X, Surdez, Didier; https://orcid.org/0000-0002-7118-7859, and et al

Abstract

PURPOSE ALK-activating mutations are identified in approximately 10% of newly diagnosed neuroblastomas and ALK amplifications in a further 1%-2% of cases. Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, will soon be given alongside induction chemotherapy for children with ALK-aberrant neuroblastoma. However, resistance to single-agent treatment has been reported and therapies that improve the response duration are urgently required. We studied the preclinical combination of lorlatinib with chemotherapy, or with the MDM2 inhibitor, idasanutlin, as recent data have suggested that ALK inhibitor resistance can be overcome through activation of the p53-MDM2 pathway. EXPERIMENTAL DESIGN We compared different ALK inhibitors in preclinical models prior to evaluating lorlatinib in combination with chemotherapy or idasanutlin. We developed a triple chemotherapy (CAV: cyclophosphamide, doxorubicin, and vincristine) in vivo dosing schedule and applied this to both neuroblastoma genetically engineered mouse models (GEMM) and patient-derived xenografts (PDX). RESULTS Lorlatinib in combination with chemotherapy was synergistic in immunocompetent neuroblastoma GEMM. Significant growth inhibition in response to lorlatinib was only observed in the ALK-amplified PDX model with high ALK expression. In this PDX, lorlatinib combined with idasanutlin resulted in complete tumor regression and significantly delayed tumor regrowth. CONCLUSIONS In our preclinical neuroblastoma models, high ALK expression was associated with lorlatinib response alone or in combination with either chemotherapy or idasanutlin. The synergy between MDM2 and ALK inhibition warrants further evaluation of this combination as a potential clinical approach for children with neuroblastoma.

Published
2023

12. Supplementary Tables from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Author

Yogev, Orli, primary, Almeida, Gilberto S., primary, Barker, Karen T., primary, George, Sally L., primary, Kwok, Colin, primary, Campbell, James, primary, Zarowiecki, Magdalena, primary, Kleftogiannis, Dimitrios, primary, Smith, Laura M., primary, Hallsworth, Albert, primary, Berry, Philip, primary, Möcklinghoff, Till, primary, Webber, Hannah T., primary, Danielson, Laura S., primary, Buttery, Bliss, primary, Calton, Elizabeth A., primary, da Costa, Barbara M., primary, Poon, Evon, primary, Jamin, Yann, primary, Lise, Stefano, primary, Veal, Gareth J., primary, Sebire, Neil, primary, Robinson, Simon P., primary, Anderson, John, primary, and Chesler, Louis, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Fig. 3 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Author

Yogev, Orli, primary, Almeida, Gilberto S., primary, Barker, Karen T., primary, George, Sally L., primary, Kwok, Colin, primary, Campbell, James, primary, Zarowiecki, Magdalena, primary, Kleftogiannis, Dimitrios, primary, Smith, Laura M., primary, Hallsworth, Albert, primary, Berry, Philip, primary, Möcklinghoff, Till, primary, Webber, Hannah T., primary, Danielson, Laura S., primary, Buttery, Bliss, primary, Calton, Elizabeth A., primary, da Costa, Barbara M., primary, Poon, Evon, primary, Jamin, Yann, primary, Lise, Stefano, primary, Veal, Gareth J., primary, Sebire, Neil, primary, Robinson, Simon P., primary, Anderson, John, primary, and Chesler, Louis, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Fig. 1 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Author

Yogev, Orli, primary, Almeida, Gilberto S., primary, Barker, Karen T., primary, George, Sally L., primary, Kwok, Colin, primary, Campbell, James, primary, Zarowiecki, Magdalena, primary, Kleftogiannis, Dimitrios, primary, Smith, Laura M., primary, Hallsworth, Albert, primary, Berry, Philip, primary, Möcklinghoff, Till, primary, Webber, Hannah T., primary, Danielson, Laura S., primary, Buttery, Bliss, primary, Calton, Elizabeth A., primary, da Costa, Barbara M., primary, Poon, Evon, primary, Jamin, Yann, primary, Lise, Stefano, primary, Veal, Gareth J., primary, Sebire, Neil, primary, Robinson, Simon P., primary, Anderson, John, primary, and Chesler, Louis, primary

Published
2023
Full Text
View/download PDF

15. Data from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Author

Yogev, Orli, primary, Almeida, Gilberto S., primary, Barker, Karen T., primary, George, Sally L., primary, Kwok, Colin, primary, Campbell, James, primary, Zarowiecki, Magdalena, primary, Kleftogiannis, Dimitrios, primary, Smith, Laura M., primary, Hallsworth, Albert, primary, Berry, Philip, primary, Möcklinghoff, Till, primary, Webber, Hannah T., primary, Danielson, Laura S., primary, Buttery, Bliss, primary, Calton, Elizabeth A., primary, da Costa, Barbara M., primary, Poon, Evon, primary, Jamin, Yann, primary, Lise, Stefano, primary, Veal, Gareth J., primary, Sebire, Neil, primary, Robinson, Simon P., primary, Anderson, John, primary, and Chesler, Louis, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Fig. 6 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Author

Yogev, Orli, primary, Almeida, Gilberto S., primary, Barker, Karen T., primary, George, Sally L., primary, Kwok, Colin, primary, Campbell, James, primary, Zarowiecki, Magdalena, primary, Kleftogiannis, Dimitrios, primary, Smith, Laura M., primary, Hallsworth, Albert, primary, Berry, Philip, primary, Möcklinghoff, Till, primary, Webber, Hannah T., primary, Danielson, Laura S., primary, Buttery, Bliss, primary, Calton, Elizabeth A., primary, da Costa, Barbara M., primary, Poon, Evon, primary, Jamin, Yann, primary, Lise, Stefano, primary, Veal, Gareth J., primary, Sebire, Neil, primary, Robinson, Simon P., primary, Anderson, John, primary, and Chesler, Louis, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Fig. 2 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Author

Yogev, Orli, primary, Almeida, Gilberto S., primary, Barker, Karen T., primary, George, Sally L., primary, Kwok, Colin, primary, Campbell, James, primary, Zarowiecki, Magdalena, primary, Kleftogiannis, Dimitrios, primary, Smith, Laura M., primary, Hallsworth, Albert, primary, Berry, Philip, primary, Möcklinghoff, Till, primary, Webber, Hannah T., primary, Danielson, Laura S., primary, Buttery, Bliss, primary, Calton, Elizabeth A., primary, da Costa, Barbara M., primary, Poon, Evon, primary, Jamin, Yann, primary, Lise, Stefano, primary, Veal, Gareth J., primary, Sebire, Neil, primary, Robinson, Simon P., primary, Anderson, John, primary, and Chesler, Louis, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Fig. 5 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Author

Yogev, Orli, primary, Almeida, Gilberto S., primary, Barker, Karen T., primary, George, Sally L., primary, Kwok, Colin, primary, Campbell, James, primary, Zarowiecki, Magdalena, primary, Kleftogiannis, Dimitrios, primary, Smith, Laura M., primary, Hallsworth, Albert, primary, Berry, Philip, primary, Möcklinghoff, Till, primary, Webber, Hannah T., primary, Danielson, Laura S., primary, Buttery, Bliss, primary, Calton, Elizabeth A., primary, da Costa, Barbara M., primary, Poon, Evon, primary, Jamin, Yann, primary, Lise, Stefano, primary, Veal, Gareth J., primary, Sebire, Neil, primary, Robinson, Simon P., primary, Anderson, John, primary, and Chesler, Louis, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Fig. 4 from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Author

Yogev, Orli, primary, Almeida, Gilberto S., primary, Barker, Karen T., primary, George, Sally L., primary, Kwok, Colin, primary, Campbell, James, primary, Zarowiecki, Magdalena, primary, Kleftogiannis, Dimitrios, primary, Smith, Laura M., primary, Hallsworth, Albert, primary, Berry, Philip, primary, Möcklinghoff, Till, primary, Webber, Hannah T., primary, Danielson, Laura S., primary, Buttery, Bliss, primary, Calton, Elizabeth A., primary, da Costa, Barbara M., primary, Poon, Evon, primary, Jamin, Yann, primary, Lise, Stefano, primary, Veal, Gareth J., primary, Sebire, Neil, primary, Robinson, Simon P., primary, Anderson, John, primary, and Chesler, Louis, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Data from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Author

Yogev, Orli, primary, Almeida, Gilberto S., primary, Barker, Karen T., primary, George, Sally L., primary, Kwok, Colin, primary, Campbell, James, primary, Zarowiecki, Magdalena, primary, Kleftogiannis, Dimitrios, primary, Smith, Laura M., primary, Hallsworth, Albert, primary, Berry, Philip, primary, Möcklinghoff, Till, primary, Webber, Hannah T., primary, Danielson, Laura S., primary, Buttery, Bliss, primary, Calton, Elizabeth A., primary, da Costa, Barbara M., primary, Poon, Evon, primary, Jamin, Yann, primary, Lise, Stefano, primary, Veal, Gareth J., primary, Sebire, Neil, primary, Robinson, Simon P., primary, Anderson, John, primary, and Chesler, Louis, primary

Published
2023
Full Text
View/download PDF

21. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

Author

Tucker, Elizabeth R., primary, Jiménez, Irene, additional, Chen, Lindi, additional, Bellini, Angela, additional, Gorrini, Chiara, additional, Calton, Elizabeth, additional, Gao, Qiong, additional, Che, Harvey, additional, Poon, Evon, additional, Jamin, Yann, additional, Martins Da Costa, Barbara, additional, Barker, Karen, additional, Shrestha, Sumana, additional, Hutchinson, J. Ciaran, additional, Dhariwal, Simran, additional, Goodman, Angharad, additional, Del Nery, Elaine, additional, Gestraud, Pierre, additional, Bhalshankar, Jaydutt, additional, Iddir, Yasmine, additional, Saberi-Ansari, Elnaz, additional, Saint-Charles, Alexandra, additional, Geoerger, Birgit, additional, Marques Da Costa, Maria Eugénia, additional, Pierre-Eugène, Cécile, additional, Janoueix-Lerosey, Isabelle, additional, Decaudin, Didier, additional, Nemati, Fariba, additional, Carcaboso, Angel M., additional, Surdez, Didier, additional, Delattre, Olivier, additional, George, Sally L., additional, Chesler, Louis, additional, Tweddle, Deborah A., additional, and Schleiermacher, Gudrun, additional

Published
2023
Full Text
View/download PDF

22. COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELS

Author

Tucker, Elizabeth R., primary, Jiménez, Irene, additional, Chen, Lindi, additional, Bellini, Angela, additional, Gorrini, Chiara, additional, Calton, Elizabeth, additional, Gao, Qiong, additional, Che, Harvey, additional, Poon, Evon, additional, Jamin, Yann, additional, Martins da Costa, Barbara, additional, Barker, Karen, additional, Shrestha, Sumana, additional, Hutchinson, J. Ciaran, additional, Dhariwal, Simran, additional, Goodman, Angharad, additional, Del Nery, Elaine, additional, Gestraud, Pierre, additional, Bhalshankar, Jaydutt, additional, Iddir, Yasmine, additional, Saberi-Ansari, Elnaz, additional, Saint-Charles, Alexandra, additional, Geoerger, Birgit, additional, Marques Da Costa, Maria Eugénia, additional, Pierre-Eugène, Cécile, additional, Janoueix-Lerosey, Isabelle, additional, Decaudin, Didier, additional, Nemati, Fariba, additional, Carcaboso, Angel M., additional, Surdez, Didier, additional, Delattre, Olivier, additional, George, Sally L., additional, Chesler, Louis, additional, Tweddle, Deborah A., additional, and Schleiermacher, Gudrun, additional

Published
2022
Full Text
View/download PDF

23. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Author

Afd Pharmaceutics, Pharmaceutics, Berlak, Mareike, Tucker, Elizabeth, Dorel, Mathurin, Winkler, Annika, McGearey, Aleixandria, Rodriguez-Fos, Elias, da Costa, Barbara Martins, Barker, Karen, Fyle, Elicia, Calton, Elizabeth, Eising, Selma, Ober, Kim, Hughes, Deborah, Koutroumanidou, Eleni, Carter, Paul, Stankunaite, Reda, Proszek, Paula, Jain, Neha, Rosswog, Carolina, Dorado-Garcia, Heathcliff, Molenaar, Jan Jasper, Hubank, Mike, Barone, Giuseppe, Anderson, John, Lang, Peter, Deubzer, Hedwig Elisabeth, Künkele, Annette, Fischer, Matthias, Eggert, Angelika, Kloft, Charlotte, Henssen, Anton George, Boettcher, Michael, Hertwig, Falk, Blüthgen, Nils, Chesler, Louis, Schulte, Johannes Hubertus, Afd Pharmaceutics, Pharmaceutics, Berlak, Mareike, Tucker, Elizabeth, Dorel, Mathurin, Winkler, Annika, McGearey, Aleixandria, Rodriguez-Fos, Elias, da Costa, Barbara Martins, Barker, Karen, Fyle, Elicia, Calton, Elizabeth, Eising, Selma, Ober, Kim, Hughes, Deborah, Koutroumanidou, Eleni, Carter, Paul, Stankunaite, Reda, Proszek, Paula, Jain, Neha, Rosswog, Carolina, Dorado-Garcia, Heathcliff, Molenaar, Jan Jasper, Hubank, Mike, Barone, Giuseppe, Anderson, John, Lang, Peter, Deubzer, Hedwig Elisabeth, Künkele, Annette, Fischer, Matthias, Eggert, Angelika, Kloft, Charlotte, Henssen, Anton George, Boettcher, Michael, Hertwig, Falk, Blüthgen, Nils, Chesler, Louis, and Schulte, Johannes Hubertus

Published
2022

24. Additional file 1 of Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Author

Berlak, Mareike, Tucker, Elizabeth, Dorel, Mathurin, Winkler, Annika, McGearey, Aleixandria, Rodriguez-Fos, Elias, da Costa, Barbara Martins, Barker, Karen, Fyle, Elicia, Calton, Elizabeth, Eising, Selma, Ober, Kim, Hughes, Deborah, Koutroumanidou, Eleni, Carter, Paul, Stankunaite, Reda, Proszek, Paula, Jain, Neha, Rosswog, Carolina, Dorado-Garcia, Heathcliff, Molenaar, Jan Jasper, Hubank, Mike, Barone, Giuseppe, Anderson, John, Lang, Peter, Deubzer, Hedwig Elisabeth, Künkele, Annette, Fischer, Matthias, Eggert, Angelika, Kloft, Charlotte, Henssen, Anton George, Boettcher, Michael, Hertwig, Falk, Blüthgen, Nils, Chesler, Louis, and Schulte, Johannes Hubertus

Abstract

Additional file 1: Figure S1: ALK inhibitor treatment of ALK-mutated neuroblastoma cell lines for optimized screeningconditions (related to Figure 1). Figure S2: Quality control of CRISPR/Cas9 knockout screen (related to Figure 1). Figure S3: Lorlatinib- and Ceritinib- resistant NBLW-R neuroblastoma cells grow as aggressive tumors in the kidney capsule of nude mice (related to Figure 3). Figure S4: Tetracycline induced NRASQ61K expression (related to Figure 4). Figure S5: Computational modeling of ALK downstream signaling using STASNet (related to Figure 6). Figure S6: MEK inhibitor treatment of ectopic NRASQ61K expression models (related to Figure 7). Figure S7: High-throughput drug screening of LAN-5 and LAN-5 NF1 KO#2 clone (related to Figure 7). Table S1. Full clinical data on neuroblastoma patients.

Published
2022
Full Text
View/download PDF

25. Additional file 6 of Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Author

Berlak, Mareike, Tucker, Elizabeth, Dorel, Mathurin, Winkler, Annika, McGearey, Aleixandria, Rodriguez-Fos, Elias, da Costa, Barbara Martins, Barker, Karen, Fyle, Elicia, Calton, Elizabeth, Eising, Selma, Ober, Kim, Hughes, Deborah, Koutroumanidou, Eleni, Carter, Paul, Stankunaite, Reda, Proszek, Paula, Jain, Neha, Rosswog, Carolina, Dorado-Garcia, Heathcliff, Molenaar, Jan Jasper, Hubank, Mike, Barone, Giuseppe, Anderson, John, Lang, Peter, Deubzer, Hedwig Elisabeth, Künkele, Annette, Fischer, Matthias, Eggert, Angelika, Kloft, Charlotte, Henssen, Anton George, Boettcher, Michael, Hertwig, Falk, Blüthgen, Nils, Chesler, Louis, and Schulte, Johannes Hubertus

Abstract

Additional file 6. Supplementary Materials and Methods.

Published
2022
Full Text
View/download PDF

28. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

Author

Poon, Evon, Liang, Tong, Jamin, Yann, Walz, Susanne, Kwok, Colin, Hakkert, Anne, Barker, Karen, Urban, Zuzanna, Thway, Khin, Zeid, Rhamy, Hallsworth, Albert, Box, Gary, Ebus, Marli E, Licciardello, Marco P, Sbirkov, Yordan, Lazaro, Glori, Calton, Elizabeth, Costa, Barbara M, Valenti, Melanie, De Haven Brandon, Alexis, Webber, Hannah, Tardif, Nicolas, Almeida, Gilberto S, Christova, Rossitza, Boysen, Gunther, Richards, Mark W, Barone, Giuseppe, Ford, Anthony, Bayliss, Richard, Clarke, Paul A, De Bono, Johann, Gray, Nathanael S, Blagg, Julian, Robinson, Simon P, Eccles, Suzanne A, Zheleva, Daniella, Bradner, James E, Molenaar, Jan, Vivanco, Igor, Eilers, Martin, Workman, Paul, Lin, Charles Y, Chesler, Louis, Poon, Evon, Liang, Tong, Jamin, Yann, Walz, Susanne, Kwok, Colin, Hakkert, Anne, Barker, Karen, Urban, Zuzanna, Thway, Khin, Zeid, Rhamy, Hallsworth, Albert, Box, Gary, Ebus, Marli E, Licciardello, Marco P, Sbirkov, Yordan, Lazaro, Glori, Calton, Elizabeth, Costa, Barbara M, Valenti, Melanie, De Haven Brandon, Alexis, Webber, Hannah, Tardif, Nicolas, Almeida, Gilberto S, Christova, Rossitza, Boysen, Gunther, Richards, Mark W, Barone, Giuseppe, Ford, Anthony, Bayliss, Richard, Clarke, Paul A, De Bono, Johann, Gray, Nathanael S, Blagg, Julian, Robinson, Simon P, Eccles, Suzanne A, Zheleva, Daniella, Bradner, James E, Molenaar, Jan, Vivanco, Igor, Eilers, Martin, Workman, Paul, Lin, Charles Y, and Chesler, Louis

Abstract

The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show that CYC065 (fadraciclib), a clinical inhibitor of CDK9 and CDK2, selectively targeted MYCN-amplified neuroblastoma via multiple mechanisms. CDK9 - a component of the transcription elongation complex P-TEFb - bound to the MYCN-amplicon superenhancer, and its inhibition resulted in selective loss of nascent MYCN transcription. MYCN loss led to growth arrest, sensitizing cells for apoptosis following CDK2 inhibition. In MYCN-amplified neuroblastoma, MYCN invaded active enhancers, driving a transcriptionally encoded adrenergic gene expression program that was selectively reversed by CYC065. MYCN overexpression in mesenchymal neuroblastoma was sufficient to induce adrenergic identity and sensitize cells to CYC065. CYC065, used together with temozolomide, a reference therapy for relapsed neuroblastoma, caused long-term suppression of neuroblastoma growth in vivo, highlighting the clinical potential of CDK9/2 inhibition in the treatment of MYCN-amplified neuroblastoma.

Published
2020

29. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

Author

UU BETA RESEARCH, Poon, Evon, Liang, Tong, Jamin, Yann, Walz, Susanne, Kwok, Colin, Hakkert, Anne, Barker, Karen, Urban, Zuzanna, Thway, Khin, Zeid, Rhamy, Hallsworth, Albert, Box, Gary, Ebus, Marli E, Licciardello, Marco P, Sbirkov, Yordan, Lazaro, Glori, Calton, Elizabeth, Costa, Barbara M, Valenti, Melanie, De Haven Brandon, Alexis, Webber, Hannah, Tardif, Nicolas, Almeida, Gilberto S, Christova, Rossitza, Boysen, Gunther, Richards, Mark W, Barone, Giuseppe, Ford, Anthony, Bayliss, Richard, Clarke, Paul A, De Bono, Johann, Gray, Nathanael S, Blagg, Julian, Robinson, Simon P, Eccles, Suzanne A, Zheleva, Daniella, Bradner, James E, Molenaar, Jan, Vivanco, Igor, Eilers, Martin, Workman, Paul, Lin, Charles Y, Chesler, Louis, UU BETA RESEARCH, Poon, Evon, Liang, Tong, Jamin, Yann, Walz, Susanne, Kwok, Colin, Hakkert, Anne, Barker, Karen, Urban, Zuzanna, Thway, Khin, Zeid, Rhamy, Hallsworth, Albert, Box, Gary, Ebus, Marli E, Licciardello, Marco P, Sbirkov, Yordan, Lazaro, Glori, Calton, Elizabeth, Costa, Barbara M, Valenti, Melanie, De Haven Brandon, Alexis, Webber, Hannah, Tardif, Nicolas, Almeida, Gilberto S, Christova, Rossitza, Boysen, Gunther, Richards, Mark W, Barone, Giuseppe, Ford, Anthony, Bayliss, Richard, Clarke, Paul A, De Bono, Johann, Gray, Nathanael S, Blagg, Julian, Robinson, Simon P, Eccles, Suzanne A, Zheleva, Daniella, Bradner, James E, Molenaar, Jan, Vivanco, Igor, Eilers, Martin, Workman, Paul, Lin, Charles Y, and Chesler, Louis

Published
2020

30. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

Author

Poon, Evon, primary, Liang, Tong, additional, Jamin, Yann, additional, Walz, Susanne, additional, Kwok, Colin, additional, Hakkert, Anne, additional, Barker, Karen, additional, Urban, Zuzanna, additional, Thway, Khin, additional, Zeid, Rhamy, additional, Hallsworth, Albert, additional, Box, Gary, additional, Ebus, Marli E., additional, Licciardello, Marco P., additional, Sbirkov, Yordan, additional, Lazaro, Glori, additional, Calton, Elizabeth, additional, Costa, Barbara M., additional, Valenti, Melanie, additional, De Haven Brandon, Alexis, additional, Webber, Hannah, additional, Tardif, Nicolas, additional, Almeida, Gilberto S., additional, Christova, Rossitza, additional, Boysen, Gunther, additional, Richards, Mark W., additional, Barone, Giuseppe, additional, Ford, Anthony, additional, Bayliss, Richard, additional, Clarke, Paul A., additional, De Bono, Johann, additional, Gray, Nathanael S., additional, Blagg, Julian, additional, Robinson, Simon P., additional, Eccles, Suzanne A., additional, Zheleva, Daniella, additional, Bradner, James E., additional, Molenaar, Jan, additional, Vivanco, Igor, additional, Eilers, Martin, additional, Workman, Paul, additional, Lin, Charles Y., additional, and Chesler, Louis, additional

Published
2020
Full Text
View/download PDF

32. In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Author

Yogev, Orli, primary, Almeida, Gilberto S., additional, Barker, Karen T., additional, George, Sally L., additional, Kwok, Colin, additional, Campbell, James, additional, Zarowiecki, Magdalena, additional, Kleftogiannis, Dimitrios, additional, Smith, Laura M., additional, Hallsworth, Albert, additional, Berry, Philip, additional, Möcklinghoff, Till, additional, Webber, Hannah T., additional, Danielson, Laura S., additional, Buttery, Bliss, additional, Calton, Elizabeth A., additional, da Costa, Barbara M., additional, Poon, Evon, additional, Jamin, Yann, additional, Lise, Stefano, additional, Veal, Gareth J., additional, Sebire, Neil, additional, Robinson, Simon P., additional, Anderson, John, additional, and Chesler, Louis, additional

Published
2019
Full Text
View/download PDF

34. Development of X-ray micro-focus computed tomography to image and quantify biofilms in central venous catheter models in vitro

Author

Niehaus, Wilmari L., primary, Howlin, Robert P., additional, Johnston, David A., additional, Bull, Daniel J., additional, Jones, Gareth L., additional, Calton, Elizabeth, additional, Mavrogordato, Mark N., additional, Clarke, Stuart C., additional, Thurner, Philipp J., additional, Faust, Saul N., additional, and Stoodley, Paul, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results